Clinical Trials Logo

Noonan Syndrome clinical trials

View clinical trials related to Noonan Syndrome.

Filter by:

NCT ID: NCT01529944 Completed - Genetic Disorder Clinical Trials

Genetic Testing of Noonan Subjects Previously Treated With Norditropin®. An Extension to Trial GHNOO-1658

Start date: September 2008
Phase: Phase 3
Study type: Interventional

This trial is conducted in Europe. The aim of this trial is to obtain the PTPN11 mutation status and investigate the impact of the PTPN11 mutation status on the effect of somatropin (Norditropin®) by use of data obtained in the GHNOO-1658 trial.

NCT ID: NCT01529840 Completed - Genetic Disorder Clinical Trials

Somatropin Effect on Linear Growth and Final Height in Subjects With Noonan Syndrome

Start date: June 1990
Phase: Phase 3
Study type: Interventional

This trial is conducted in Europe. The aim of this trial is to evaluate the effect of somatropin (Norditropin®) on final height in children with Noonan syndrome having being treated for up to 10 years with somatropin (Norditropin®) for the attainment of an optimal final height in the original trial S/GHD/004/NOO.

NCT ID: NCT00960128 Completed - Clinical trials for Chronic Kidney Disease

Observational Prospective Study on Patients Treated With Norditropin®

Start date: April 1, 2006
Phase: N/A
Study type: Observational

This observational study is conducted globally. The aim of the study is to investigate the effectiveness and safety of real-life treatment with Norditropin®. The study population will consist of children and adults who are on treatment with Norditropin® in accordance with normal clinical practice.

NCT ID: NCT00452725 Completed - Noonan Syndrome Clinical Trials

Effect of MAXOMAT ® on the Growth of Small Children to NOONAN's Syndrome

Start date: October 1997
Phase: Phase 3
Study type: Interventional

1. Clinical Objective : To improve the growth of these children 2. Genetic objective : A study of the genetics of the syndrome

NCT ID: NCT00351221 Terminated - Noonan Syndrome Clinical Trials

Research Study Using Recombinant Human Insulin-Like Growth Factor-1/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 for Children With Noonan Syndrome

Start date: n/a
Phase: Phase 2
Study type: Interventional

The trial will investigate the treatment of growth failure in children with Noonan syndrome. Abnormalities in the growth hormone (GH) – insulin-like growth factor-I (IGF-I) axis resulting in low IGF-I levels have been suggested as a possible cause of short stature seen in Noonan syndrome children. Administration of our investigational product is intended to bypass the abnormalities in the GH-IGF axis, and hopefully improve body growth.